A laboratory readout,whether a zone diameter in millimeters or a Minimum Inhibitory Concentration (MIC) in µg/mL,gets mapped against organism-specific breakpoints published by CLSI or EUCAST, producing a Susceptible, Intermediate, or Resistant category that predicts therapy success at standard doses. Method-specific variability, dose-dependence, and quality-control caveats shape each assignment.
This walkthrough explains how susceptibility categories are built, why intermediate results deserve a second look, and how you can translate the report into evidence-based care. By the end, you should be able to read any culture and sensitivity report with confidence, whether you’re sitting at a bench or beside a patient.
The Two Methods That Shape Every Susceptibility Report
Disk diffusion (the Kirby-Bauer method) places antibiotic-impregnated paper discs on a lawn of bacteria spread across Mueller-Hinton agar and measures the clear zone of inhibition in millimeters after overnight incubation. The diameter is then correlated to breakpoints; it does not represent an absolute drug concentration in the body.
Broth Microdilution and Automated Instruments
Broth microdilution exposes standardized bacterial suspensions to serial two-fold dilutions of an antibiotic and reports the Minimum Inhibitory Concentration (MIC), the lowest concentration that visibly suppresses growth, in µg/mL. Automated platforms such as Vitek 2 and BD Phoenix run miniaturized versions of the same principle and read endpoints with optical or fluorometric sensors.
Gradient Strips and Hybrid Reads
E-test and other MIC test strips carry a continuous gradient of antibiotic on a plastic strip laid across an inoculated plate. Where the elliptical inhibition zone intersects the strip, the operator reads the MIC off the printed scale, blending features of both major methods.
| Method | Output | Units | Key Limitation |
|---|---|---|---|
| Disk diffusion (Kirby-Bauer) | Zone diameter | Millimeters (mm) | Categorical only; no exact MIC |
| Broth microdilution / automated | MIC | µg/mL | ±1 dilution inherent variance |
| Gradient strip (E-test) | MIC read off ellipse | µg/mL | Trailing endpoints with some drugs |
Recognizing which method produced the report on your desk is the first interpretive step, because it dictates the units, the breakpoints, and the variability you should expect.
How MIC Values and Zone Diameters Become S, I, and R
Raw numbers on their own carry no clinical meaning. A zone of 18 mm or an MIC of 4 µg/mL only becomes actionable when mapped to organism-specific breakpoint tables published by CLSI or EUCAST, and that mapping is what produces the Susceptible, Intermediate, or Resistant category on your report.
What Each Category Actually Predicts
Susceptible (S) predicts clinical success when the drug is used at standard dosing at the site of infection. Intermediate (I) no longer signals a gray zone for you; it flags that the drug may work only at maximum dosing, at a body site where the drug concentrates (such as urine), or when free drug levels reliably exceed the MIC. Resistant (R) predicts clinical failure even with optimized dosing and generally removes the agent from your consideration.
A category assignment is a prediction about therapy, not a measurement of the bug itself. Read it that way and most confusion fades.
Why Breakpoints Are Organism-Specific
Breakpoints reflect how a species behaves pharmacokinetically and which resistance mechanisms matter. An MIC of 2 µg/mL may be Susceptible for E. coli against ceftriaxone but Resistant for Pseudomonas aeruginosa against the same drug, so you must confirm species identification before susceptibility interpretation begins.
CLSI Versus EUCAST Breakpoints and Why the Same Number Can Tell Two Stories
CLSI and EUCAST set breakpoints independently, and for many drug–organism pairs their cutoffs differ by one dilution or more. The same MIC can therefore land in different categories depending on which standard the laboratory followed for your isolate.
Category Differences That Matter Clinically
CLSI retains a Susceptible-Dose Dependent (SDD) category for selected agents, signaling that higher doses may achieve clinical success. EUCAST merged a similar concept into its redefined Intermediate (I) category, where the dose-dependent flag is folded into the intermediate label itself.
| Aspect | CLSI | EUCAST |
|---|---|---|
| Categories | S, SDD, I, R | S, I (dose-dependent), R |
| Dose-dependent signal | SDD label | Bundled inside I |
| Update cycle | Annual documents | Rolling web updates |
| Geographic use | Primarily U.S. | Primarily Europe |
Laboratories must declare which standard they use, and you should know which standard informed the report on your desk. When breakpoints produce different category assignments, the standard adopted by the testing laboratory should generally drive your clinical decision, supplemented by local resistance epidemiology from the institutional antibiogram.
Reading the Report With the Intermediate Category in Mind
An Intermediate result is a call to optimize your regimen, not a reason to discard the drug. Review achievable serum or tissue levels, weigh alternative routes, and verify the infection site before moving on.
Pharmacokinetic Drivers That Convert “I” Into Effective Therapy
For beta-lactams, time above MIC drives efficacy, so a higher or more frequent dose, prolonged infusion, or continuous infusion can shift an Intermediate into clinical territory. For fluoroquinolones and aminoglycosides, the AUC/MIC or peak/MIC ratio matters, and high-dose or synergistic combinations sometimes rescue an Intermediate agent you would otherwise have to abandon.
Site of Infection Changes Everything
Drugs that concentrate in urine (such as nitrofurantoin or fosfomycin) often succeed against Intermediate urinary isolates even when systemic levels would fail. Conversely, an Intermediate agent for meningitis is usually a non-starter because cerebrospinal fluid penetration is too low.
Confirm that the isolate identification and infection source match the breakpoint assumption. Breakpoints are organism- and sometimes specimen-specific, and misaligned assumptions lead to misapplied categories.
Red Flags That Should Override the Printed Category
Standard breakpoints cover most situations, but several flags should trigger escalation or repeat testing regardless of what the category says.
Quality Control Failures Invalidate the Run
Confirm that reference strains (ATCC 25923 for disk diffusion, ATCC 29213 for MIC panels) passed on the same run. An out-of-control QC invalidates every patient result on that tray, even if individual categories look plausible to the eye.
Phenotypic Expert Rules Demand Confirmation
Alert flags such as vancomycin-resistant S. aureus, carbapenem-resistant Enterobacterales, or inducible clindamycin resistance (a positive D-test) require confirmation and escalation regardless of the categorical result. These phenotypes carry infection-control and therapeutic consequences that the routine category alone cannot convey.
Method-Specific Pitfalls Can Silently Shift Results
Trailing endpoints in sulfonamides, swarming Proteus, thin growth with fastidious organisms, and ±1 dilution variance between broth microdilution and E-test can push a result across a breakpoint without obvious warning. Question borderline values that could swing either way for your isolate.
Antibiogram Disagreements Warrant a Second Look
A category result that conflicts with the institution’s antibiogram warrants repeat testing, species confirmation, or referral to a reference laboratory. Local cumulative resistance patterns often catch emerging mechanisms before the printed category reflects them.
Turning the Report Into an Evidence-Based Therapy Decision
A susceptibility report changes value when it changes a decision for you. The following sequence keeps your workflow honest and reproducible.
Step 1: Confirm the Foundations
- Confirm organism and method: Check that species identification and testing method are stated before applying any clinical logic.
- Confirm breakpoint standard: Note whether CLSI or EUCAST breakpoints informed the category, since the same number can carry different meanings.
- Confirm QC validity: Verify the run’s reference-strain performance before acting on patient results.
Step 2: Rank Susceptible Agents by Clinical Fit
Among susceptible options, narrow your list by spectrum (favor narrower agents when equally effective), tissue penetration at the infection site, allergy profile, and renal or hepatic dosing constraints. A “Susceptible” label doesn’t make two drugs interchangeable; pharmacokinetics and host factors routinely break ties.
Step 3: Revisit Intermediate Results With a Dose-Optimization Plan
When no fully susceptible agent is available, clinicians should revisit Intermediate results with explicit dose optimization in mind: extended or continuous infusion for beta-lactams, high-dose fluoroquinolone regimens, synergistic beta-lactam plus aminoglycoside combinations. Document the rationale so the choice survives review.
Step 4: Apply Institutional Resistance Context
Use the institution’s antibiogram to anticipate resistance that standard breakpoints alone may not flag. Local prevalence of ESBL producers, MRSA, or carbapenemase carriage often shifts empirical choices long before national guidelines update.
Even a well-reasoned decision sits on top of the very institution-level data that shapes the antibiogram you are interpreting.
A Practical Checklist Before Therapy
- Verify identification: Confirm species before accepting the category.
- Verify method: Note whether the report comes from disk diffusion, MIC, or gradient strip.
- Verify standard: Identify which breakpoint set (CLSI or EUCAST) was applied.
- Verify QC: Check that reference-strain controls passed.
- Verify site: Confirm the breakpoint assumption matches the infection source.
Final Thoughts
Interpreting antimicrobial susceptibility results is a translation exercise. The laboratory converts raw growth or inhibition into a category designed to predict therapy success, but the prediction depends on the method, the breakpoint standard, the species, and the site of infection. Treating the printed category as the starting point rather than the final answer keeps therapy aligned with both the bench and the bedside.
FAQ
What does intermediate susceptibility mean in an antibiotic sensitivity report?
Intermediate susceptibility signals that the drug may still work for you, but only at maximum dosing, at a body site where the drug concentrates, or when free drug levels reliably exceed the MIC. It is a call to optimize your regimen, not to discard the agent.
How are MIC breakpoints determined?
Breakpoints are set by committees at CLSI and EUCAST using pharmacokinetic-pharmacodynamic data, clinical outcome studies, and resistance-mechanism distributions. They are organism-specific and updated regularly as new dosing evidence emerges.
What is the difference between MIC and zone diameter in susceptibility testing?
An MIC is the lowest drug concentration (in µg/mL) that visibly suppresses growth in a broth or strip system. A zone diameter (in mm) is the width of the inhibition area around a disc on agar; it correlates with MIC through breakpoints but does not represent an exact drug concentration.
Why might an organism be reported susceptible in vitro but fail therapy in vivo?
In vitro results assume standard dosing and adequate drug penetration at the infection site. Abscesses, foreign bodies, poor tissue perfusion, or inadequate free-drug levels can all undermine a Susceptible category in the actual patient.
How do CLSI and EUCAST breakpoints compare?
Both organizations publish breakpoint tables, but they set cutoffs independently and the numbers often differ by one dilution or more. CLSI retains a separate Susceptible-Dose Dependent category, while EUCAST folds dose-dependence into its Intermediate label.
